Cipla – SRK Analytics

Cipla Secures US FDA Approval for Generic Advair Diskus Across All Strengths

Indian pharmaceutical major Cipla Limited has secured final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for generic Advair Diskus. The regulatory clearance…

Prasenjit Bhowmik July 28, 2026

Business Insights

Cipla Reaffirms Full-Year Profit Guidance as $1 Billion US Revenue Target Paves Way for FY27 Growth Ramp-Up

Indian pharmaceutical major Cipla Limited announced it is maintaining its full-year EBITDA margin guidance of 18.5% to 20%, anchored by a projected U.S. sales run rate of $1 billion by…

Prasenjit Bhowmik July 23, 2026

Market

Cipla’s Strategic Outlook: Navigating Growth in the Global Pharmaceutical Landscape

As global demand for affordable healthcare continues to escalate, Mumbai-based pharmaceutical giant Cipla Limited is positioning itself for a pivotal three-year growth trajectory. With rising exports and a robust pipeline…

Prasenjit Bhowmik July 3, 2026